Comparison of Blood Cardioplegia and Custodiol

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bjørn Braathen, Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT01941459
First received: May 7, 2012
Last updated: September 12, 2013
Last verified: September 2013
  Purpose

Thru the last 20 years it has been a discussion witch solution that gives the best myocardial protection during cardiac arrest by heart operations.

  • It has been a tendency that a blood based cardioplegia gives a better protection bye long ischemic times but it has not been possible too conclude in this matter.
  • The investigators have two groups of cardioplegia, the blood based and, the crystalloid based cardioplegia.
  • It has been done a lot of studies to see what kind of cardioplegia that gives the best myocardial protection. Different temperature, different amount and content, retrograde or antegrade or both, contentiously and further on have been tested without a clear conclusion.
  • The investigators decided to make a study with a cohort of patients as homogenous as possible with a cross clamp time around 70 min.
  • Adult patients' with a severe aortic stenoses without any other significant heart disease was included in our prospective randomised study.
  • Patients with additional significant coronary artery disease (≥ 50% stenoses) were excluded from the study.
  • The investigators used the well known biomarkers CK-MB and troponin-T too evaluate the myocardial damage.

Condition
Mitral Insufficiencies
Myocardial Protection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Comparison of Blood Cardioplegia and Custodiol on Patients Operated for Significant Mitral Valve Innsufisiens. An Prospective, Randomized Two-center Study.

Further study details as provided by Oslo University Hospital:

Primary Outcome Measures:
  • CK-MB ,troponin-T [ Time Frame: 72 hours ] [ Designated as safety issue: No ]

Enrollment: 76
Study Start Date: March 2007
Study Completion Date: January 2010
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
1 Custodiol
Custodiol
2 Blood cardioplegia
Blood cardioplegia

Detailed Description:

Objective: Myocardial protection during a cardiac arrest is mostly managed with cardioplegia. To day we normally used a blood or crystalloid based solutions. It has been published a lot of papers comparing the too groups with different results. To our knowledge no prospective, randomized study has compared modified St Thomas based Blood and Crystalloid cardioplegia on the acknowledged markers (CK-MB, troponin-T) of myocardial damage during aortic valve replacement on patients without additional significant coronary artery disease.

Methods: 100 patients with aorta stenoses undergoing aortic valve replacement without significant coronary artery stenoses or other significant concomitant heart valve disease were included in the study. They were given antegrade cold blood or cold crystalloid cardioplegia delivered through the coronary Ostia every 20 min throughout the period of aortic cross-clamp. CK-MB and troponin-T were compared between the two groups.

Published 2010 in the journal of thoracic and cardiovascular surgery.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Between Mars 2007 and December 2009, 80 consecutive patients undergoing elective mitral valve surgery for mitral regurgitation at Oslo University Hospital Ullevål, Oslo, Norway and Sahlgrenska University Hospital, Gothenburg, Sweden were included in the study after informed written consent.

Criteria

The study protocol was approved by the local ethical committees. Eligible for operation were:

Inclution Criteria

  • patients with mitral regurgitation equal to or larger than grade 3 out of 4.
  • Ablation for atrial fibrillation was the only concomitant procedure that was allowed in addition to mitral valve surgery and these patients were block-randomized to ensure equally many patients with ablation in the two groups of cardioplegia.

Exclusion Criteria

  • Patients with any other concomitant heart valve disease or coronary artery stenoses (≥ 50%) were excluded from the study.
  • Age below 18
  • Pregnant
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01941459

Locations
Norway
thoraxkirurgisk avd, UUS
Oslo, Norway
Sponsors and Collaborators
Ullevaal University Hospital
Investigators
Study Director: Theis Tønnessen, prof.dr.med Thoraxkirurgisk avd. UUS
Study Chair: Bjørn Braathen, med.doc Thoraxkir.avd. UUS
  More Information

No publications provided

Responsible Party: Bjørn Braathen, MD. Ph.D, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT01941459     History of Changes
Other Study ID Numbers: 2007-001780-30
Study First Received: May 7, 2012
Last Updated: September 12, 2013
Health Authority: Norway:National Committee for Medical and Health Research Ethics

Keywords provided by Oslo University Hospital:
CK-MB
troponin-T

Additional relevant MeSH terms:
Mitral Valve Insufficiency
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on April 15, 2014